Metsera (MTSR) BofA Securities 2025 Healthcare Conference summary

Strategic focus and market outlook

• Targeting the obesity market with nutrient-stimulated hormone analogs, especially GLP-1, emphasizing early-stage opportunities for pathway combinations and scalable peptide engineering.

• Identifies scalability and tolerability as key challenges in current obesity treatments, aiming for monthly or longer dosing and improved oral peptide delivery.

• Highlights the need for multi-hormone combinations to achieve higher efficacy and better tolerability.

• Positions portfolio to address market friction from complex titration and tolerability issues.

Pipeline and clinical development

• Three clinical assets: ultra-long-acting GLP-1 (phase 2), monthly amylin (phase 1), and a range of orals, with two entering the clinic mid-year.

• MET-097, the lead GLP-1 asset, shows a 380-hour half-life, enabling monthly dosing and titration-free regimens.

• MET-097 demonstrates dual agonist-like efficacy at lower doses and placebo-like tolerability, with up to 14.2% placebo-adjusted weight loss at 16 weeks.

• MET-233, an ultra-long-acting amylin, is highly potent, combinable with MET-097, and expected to show similar durability.

• Early-stage work includes a mono GIP agonist (MET-34) and additional hormone pathways for future combinations.

Oral peptide innovation and manufacturing

• Oral strategy leverages improved bioavailability and peptide potency to achieve scalable dosing, targeting single-digit milligram doses.

• MET-224 and oral MET-097 to enter the clinic mid-year, with comparative phase 1 data expected later this year.

• Manufacturing advantages stem from high potency and durability, reducing API requirements and device usage by up to 75% compared to competitors.

• Strategic partnership with Amnio Pharmaceuticals supports global supply chain flexibility and greenfield plant development.